Separation and Characterization of New Components and Impurities in Leucomycin by Multiple Heart-Cutting Two-Dimensional Liquid Chromatography Combined with Ion Trap/Time-of-Flight Mass Spectrometry
- 9 Downloads
In this study, nine new components and six impurities in leucomycin were discovered. A method was developed for the separation and characterization of new components and impurities in leucomycin by multiple heart-cutting two-dimensional liquid chromatography combined with ion trap/time-of-flight mass spectrometry in both positive and negative electrospray ionization modes. With this method, a non-volatile buffer solution was used as mobile phase in the first-dimensional system for good separation. Eluent of each peak from the first-dimensional system was trapped by a switching valve and sent to the liquid chromatography-mass spectrometry system using a volatile mobile phase. The complete fragmentation patterns of the new components and degradation impurities were deduced based on MSn data. The structures of nine new components in leucomycin were deduced as unsaturated ketone in the 16-membered ring of leucomycin. The structures of six impurities were characterized for the first time, four of which were acid degradation products, and the other two were process impurities. The correlation between impurities and the purification process of leucomycin was also studied. The degradation impurities were produced during purification of leucomycin fermentation broth, which requires a low-pH environment. Based on the characterization of impurities, this study not only revealed the mechanism of impurity production, thus providing guidance to pharmaceutical companies for manufacturing process improvement and impurity reduction, but also provided a scientific basis for further improvement of official monographs in pharmacopoeias.
KeywordsKitasamycin Leucomycin Impurity Multiple heart-cutting two-dimensional liquid chromatography Ion trap/time-of-flight mass spectrometry
This work was supported by Key Technologies and Standards for Drug Consistency Assessment of National Science and Technology Major Project (No. 2017ZX09101001).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Liu QQ (2003) Improved preparation of kitasamycin tablets. Chin J Pharm 34:22–23Google Scholar
- 2.Yang Q, Ma SH, Hu M, Hu CQ (2006) Determination of active ingredients of kitasamycin by high performance liquid chromatography. Chin J Anal Chem 34:95–99Google Scholar
- 4.Filadoro F, Cipriani P, Ravagnan L (1968) Antibacterial effect in vitro and in vivo of kitasamycin. Antibiotica 6:5–23Google Scholar
- 5.ICH Harmonised Tripartite Guideline Q3A(R) (2006) Impurities in new salt substances, The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use. https://www.ich.org/products/guidelines/quality/article/quality-guidelines.html. Accessed 25 Jan 2019
- 8.Chen X (2011) Study on contents determination methodology of kitasamycinum composition in kitasamycin tartrate for injection by HPLC. J Hubei Univ Med 30:588–590Google Scholar
- 9.Hu M, Hu CQ (2006) Identification of the components and products of hydrolysis in acetyl leucomycin by LC-MS. Acta Pharm Sin 41:476–480Google Scholar
- 10.Zhu SQ, Niu CQ (2007) LC-MS analysis of components of kitasamycin. Chin J Antibiot 32:478–480Google Scholar
- 13.Wang MJ, Hu CQ (2013) Impurity profiling of macrolide antibiotics by liquid chromatography-mass spectrometry. Acta Parm Sin 48:642–647Google Scholar
- 16.Shipkova PA, Heimark L, Bartner PL, Chen G, Pramanik BN, Ganguly AK, Cody RB, Kusai A (2000) High-resolution LC/MS for analysis of minor components in complex mixtures: negative ion ESI for identification of impurities and degradation products of a new oligosaccharide antibiotic. J Mass Spectrom 35:1252–1258CrossRefGoogle Scholar
- 18.Yang Q, Wang ZY, Tang SF (2016) Application of two-dimensional UPLC-QTof MS technology in the study of the impurity profile of bleomycin hydrochloride*. Chin J Pharm Anal 36:1231–1242Google Scholar
- 19.Long Z, Zhan ZQ, Guo ZM, Li YQ, Li CK, Yao JT, Ji F, Zheng X, Ren B, Huang TH (2019) A novel two-dimensional liquid chromatography-mass spectrometry method for direct drug impurity identification from HPLC eluent containing ion-pairing reagent in mobile phases. Anal Chim Acta 1049:105–114CrossRefGoogle Scholar
- 23.National Pharmacopoeia Committee (2015) Chinese pharmacopoeia, part 2, 2015th edn. China Medical Science and Technology Press, BeijingGoogle Scholar
- 24.Editorial Board of Japanese Pharmaceutical (2016) The Japanese pharmacopoeia, Seventeenth edn. Ministry of Health, Labour and WelfareGoogle Scholar
- 28.Zhang X, Li J, Wang C, Song DQ, Hu CQ (2017) Identification of impurities in macrolides by liquid chromatography–mass spectrometric detection and prediction of retention times of impurities by constructing quantitative structure–retention relationship (QSRR). J Pharm Biomed Anal 145:262–272CrossRefGoogle Scholar